An interventional study of Synbiotic Supplement and Placebo in Obesity, sponsored by Tehran University of Medical Sciences. Enrolling by invitation at 1 site in Iran. Open to female participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-17.
Sponsored by Tehran University of Medical Sciences · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Obesity is a complex, multifactorial disease driven by metabolic dysfunction, chronic low-grade inflammation, oxidative stress, and gut microbiota dysbiosis. The pathogenesis of obesity is closely linked to white adipose tissue (WAT) dysfunction, particularly the dysregulation of lipogenic and adipogenic pathways, leading to adipocyte hypertrophy and ectopic fat deposition. Although sleeve gastrectomy is a gold-standard intervention for severe obesity, a subset of patients experiences suboptimal long-term weight loss and cardiometabolic improvements, potentially due to persistent inflammation and metabolic resistance.
The gut-adipose axis has emerged as a critical therapeutic target. Modulation of the gut microbiome through synbiotic supplementation may alleviate metabolic endotoxemia and systemic inflammation, thereby improving energy homeostasis. However, the impact of presurgical synbiotic intervention on adipose tissue remodeling in patients undergoing sleeve gastrectomy remains largely unexplored.
This triple-blind, randomized controlled trial (RCT) aims to evaluate the efficacy of synbiotic supplementation in obese women candidates for sleeve gastrectomy. The objective is to investigate the effect of synbiotics on the expression of key lipogenic and adipogenic transcriptional factors (e.g., SREBP-1c, C/EBPα, PPARγ, LXRs) and rate-limiting enzymes (e.g, FAS, ACC) in white adipose tissue.
The study hypothesis is that presurgical synbiotic intervention will modulate adipose tissue function, thereby enhancing postoperative weight loss and improving metabolic profiles. The study aims to provide evidence for a potential therapeutic strategy to optimize clinical outcomes in bariatric patients by targeting the molecular mechanisms underlying adipose tissue expansion.
11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.
This study's planned enrollment of 50 is below the median of 67 across 9,023 interventional studies indexed under Obesity.
Browse Obesity studies →Tehran University of Medical Sciences is the lead sponsor of 232 studies on the registry; 13 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Inclusion Criteria
Participants must meet all of the following criteria:
Participants will be excluded if any of the following criteria apply:
Participants who consume less than 90% of the prescribed supplements during the intervention period will be classified as having inadequate adherence.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive one sachet of synbiotic supplement daily for 12 weeks. Each sachet contains Lactobacillus acidophilus, Lactobacillus rhamnosus, Lactobacillus plantarum, Streptococcus thermophilus, Bifidobacterium longum (1×10⁹ CFU/sachet total) and inulin. Supplements will be distributed monthly.
Dietary Supplement: Synbiotic Supplement
Participants will receive one sachet of placebo (containing cellulose) daily for 12 weeks. Supplements will be distributed monthly.
Dietary Supplement: Placebo
In the intervention group, participants will receive one sachet of synbiotic supplement orally once daily for 12 weeks. Each sachet contains a combination of Lactobacillus acidophilus, Lactobacillus rhamnosus, Lactobacillus plantarum, Streptococcus thermophilus, and Bifidobacterium longum, providing a total of 1 × 10⁹ colony-forming units, along with inulin as a prebiotic component.
In the placebo , participants will receive one sachet of placebo containing cellulose, identical in appearance, taste, and packaging to the active supplement to maintain blinding. Both interventions will be administered orally once daily for 12 weeks, with supplements dispensed monthly to support participant compliance and adherence throughout the study.
Fatty Acid Synthase (FAS) mRNA level and protein level in subcutaneous and abdominal adipose tissue
Adipose tissue samples will be collected from obese women candidates for sleeve gastrectomy during surgery 12 weeks post-intervention. mRNA levels will be quantified using real-time quantitative PCR (qRT-PCR), and protein expression will be assessed by Western blot analysis.
Time frame: 12 weeks after intervention
Sterol Regulatory Element-Binding Protein-1c (SREBP) mRNA and protein levels in abdominal and subcutaneous adipose tissue
Adipose tissue samples will be collected from obese women candidates for sleeve gastrectomy during surgery 12 weeks post-intervention. mRNA levels will be quantified using real-time quantitative PCR (qRT-PCR), and protein expression will be assessed by Western blot analysis
Time frame: 12 weeks after intervention
Acetyl-CoA carboxylase (ACC) mRNA and protein levels in subcutaneous and abdominal adipose tissue
Adipose tissue samples will be collected from obese women candidates for sleeve gastrectomy during surgery 12 weeks post-intervention. mRNA levels will be quantified using real-time quantitative PCR (qRT-PCR), and protein expression will be assessed by Western blot analysis
Time frame: 12 weeks after intervention
Peroxisome proliferator-activated receptor gamma (PPAR-γ ) mRNA level in abdominal and subcutaneous adipose tissue
Adipose tissue samples will be collected from obese women candidates for sleeve gastrectomy during surgery 12 weeks post-intervention. mRNA levels will be quantified using real-time quantitative PCR (qRT-PCR).
Time frame: 12 weeks after intervention
Peroxisome proliferator-activated receptor-γ coactivator 1-α (PGC-1α) mRNA level in abdominal and subcutaneous adipose tissue
Adipose tissue samples will be collected from obese women candidates for sleeve gastrectomy during surgery 12 weeks post-intervention. mRNA levels will be quantified using real-time quantitative PCR (qRT-PCR).
Time frame: 12 weeks after intervention
C/EBP-alpha (CCAAT/enhancer-binding protein alpha) mRNA level in abdominal and subcutaneous adipose tissue
Adipose tissue samples will be collected from obese women candidates for sleeve gastrectomy during surgery 12 weeks post-intervention. mRNA levels will be quantified using real-time quantitative PCR (qRT-PCR).
Time frame: 12 weeks after intervention
LXRα (Liver X Receptor alpha) mRNA levels in abdominal and subcutaneous adipose tissues
Adipose tissue samples will be collected from obese women candidates for sleeve gastrectomy during surgery 12 weeks post-intervention. mRNA levels will be quantified using real-time quantitative PCR (qRT-PCR).
Time frame: 12 weeks after intervention
Changes in fasting blood glucose
Fasting blood glucose (FBS) levels will be measured in serum using standard laboratory methods after an overnight fast of at least 8 hours.Results will be reported in mg/dL.
Time frame: Baseline, at the end of the 12-week intervention (2 days before sleeve gastrectomy), and 3 and 6 months after surgery.
Changes in fasting serum insulin
Changes in fasting serum insulin levels will be measured using standard laboratory methods after an overnight fast of at least 8 hours. Results will be reported in IU/ml.
Time frame: Baseline, at the end of the 12-week intervention (2 days before sleeve gastrectomy), and 6 months after surgery.
Changes in lipid profile
Changes in lipid profile in serum, including total cholesterol (mg/dl), triglycerides , high-density lipoprotein cholesterol (HDL-C) (mg/dl), and low-density lipoprotein cholesterol (LDL-C) (mg/dl) will be measured using standard laboratory methods after an overnight fast of at least 8 hours. Results will be reported in mg/dl.
Time frame: Baseline, at the end of the 12-week intervention (2 days before sleeve gastrectomy), and 3 months and 6 months after surgery.
Changes in liver enzymes, including alanine aminotransferase (ALT), aspartate aminotransferase (AST)
Alanine aminotransferase (ALT) (IU/ml), aspartate aminotransferase (AST)will be measured in serum using standard laboratory methods after an overnight fast of at least 8 hours. Results will be reported in IU/ml.
Time frame: Baseline, at the end of the 12-week intervention (2 days before sleeve gastrectomy), and 3 months and 6 months after surgery.
Changes in urea levels
Serum urea concentrations will be measured using standard clinical laboratory methods. Results will be reported in mg/dL.
Time frame: Baseline, at the end of the 12-week intervention (2 days before sleeve gastrectomy), and 3 months and 6 months after surgery.
Changes in creatinine levels
Serum creatinine concentrations will be measured using standard clinical laboratory methods. Results will be reported in mg/dL. Changes from baseline will be calculated at each follow-up assessment.
Time frame: Baseline, at the end of the 12-week intervention (2 days before sleeve gastrectomy), and 3 months and 6 months after surgery.
Change in Quality of Life
Quality of life will be assessed using a validated, standardized questionnaire. Total scores will be calculated according to the instrument's scoring guidelines, with higher or lower scores interpreted according to the specific questionnaire used. Changes in quality-of-life scores will be calculated as the difference between the final assessment and baseline assessment.
Time frame: Baseline, at the end of the 12-week intervention (2 days before sleeve gastrectomy), and 3 months and 6 months after surgery.
Change in food addiction symptoms
Food addiction symptoms will be assessed using the modified Yale Food Addiction Scale. Scores will be calculated according to the scale's scoring guidelines. Changes in food addiction symptom scores from baseline will be evaluated at each follow-up assessment.
Time frame: Baseline, at the end of the 12-week intervention (2 days before sleeve gastrectomy), and 3 months and 6 months after surgery.
Changes in Eating Behavior
Eating behavior will be assessed using the study-specified eating behavior questionnaire. Questionnaire scores will be calculated according to the instrument's scoring guidelines. Changes in scores from baseline will be evaluated at each follow-up assessment.
Time frame: Baseline, at the end of the 12-week intervention (2 days before sleeve gastrectomy), and 3 months and 6 months after surgery.
Change in physical activity
Physical activity will be assessed using a validated, standardized physical activity questionnaire. Changes in physical activity levels and scores from baseline will be evaluated at each follow-up assessment according to the questionnaire's scoring guidelines.
Time frame: Baseline, at the end of the 12-week intervention (2 days before sleeve gastrectomy), and 3 months and 6 months after surgery.
Changes in Body weight
Body weight will be measured at baseline and at the end of the intervention using a calibrated digital scale, with participants wearing light clothing and no shoes. Weight reported in kilograms (kg).
Time frame: Baseline, at the end of the 12-week intervention (2 days before sleeve gastrectomy), and 3 months and 6 months after surgery.
Change in waist circumference
Waist circumference will be measured in centimeters (cm) using a non-stretchable measuring tape according to standardized anthropometric procedures.
Time frame: Baseline, at the end of the 12-week intervention (2 days before sleeve gastrectomy), and 3 months and 6 months after surgery.
Change in hip circumference
Hip circumference will be measured in centimeters (cm) using a non-stretchable measuring tape according to standardized anthropometric procedures.
Time frame: Baseline, at the end of the 12-week intervention (2 days before sleeve gastrectomy), and 3 months and 6 months after surgery.
Change in systolic and diastolic blood pressure
Systolic and diastolic blood pressure will be measured in millimeters of mercury (mmHg) using a validated blood pressure monitor under standardized conditions.
Time frame: Baseline, at the end of the 12-week intervention (2 days before sleeve gastrectomy), and 3 months and 6 months after surgery.
Change in total body fat percentage
Total body fat percentage will be assessed using bioelectrical impedance analysis (BIA) and expressed as a percentage (%).
Time frame: Baseline, at the end of the 12-week intervention (2 days before sleeve gastrectomy), and 3 months and 6 months after surgery.
Change in fat-free mass
Fat-free mass will be assessed using bioelectrical impedance analysis (BIA) and expressed in kilograms (kg).
Time frame: Baseline, at the end of the 12-week intervention (2 days before sleeve gastrectomy), and 3 months and 6 months after surgery.
Change in muscle mass
Muscle mass will be assessed using bioelectrical impedance analysis (BIA) and expressed in kilograms (kg).
Time frame: Baseline, at the end of the 12-week intervention (2 days before sleeve gastrectomy), and 3 months and 6 months after surgery.
Change in body mass index (BMI)
Body mass index (BMI) will be calculated as body weight in kilograms divided by the square of height in meters (kg/m²). Height in meter will be measured at baseline for anthropometric characterization.Body weight and height will be measured using standardized procedures.
Time frame: Baseline, at the end of the 12-week intervention (2 days before sleeve gastrectomy), and 3 months and 6 months after surgery.
Plan to share: No
No publications or documents are linked to this record.
Started Oct 2026 (actual). Primary completion is estimated for Sep 2027, 11 months after the start.
Of 3,690 non-industry interventional studies with no phase under Obesity, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 11 months is below that.
Counting every sponsor, half of 3,853 studies reached it within 22 months; a quarter within 9 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Tehran University of Medical Sciences →